


CURRICULUM VITAE

Assoc. Prof. Priv. Doz. Dr. med. univ. Lukas Weseslindtner

ADDRESS

Center for Virology
Medical University of Vienna
Kinderspitalgasse 15; A-1090 Vienna, Austria
lukas.weseslindtner@meduniwien.ac.at



copyright: MUW, feelimage

PERSONAL INFORMATION

Date of Birth	7 th of October 1976
Place of Birth	Vienna, Austria
Nationality	Austria
Marital Status	married, one son

EDUCATION

1987 - 1995	humanistic high school „Wasagasse“ in Vienna
1995 - 2003	Medical studies at the University of Vienna (N201)
	Graduation to a doctor of medicine (Dr. med. univ.)
2004	Title of the doctoral thesis: „The establishment of a test for the simultaneous analysis of proliferation and cytokine production of Hepatitis C Virus-specific CD4+ T-helper cells“

ACADEMIC AND CLINICAL CAREER

2004 - 2006	Post-doc at the Clinical Institute for Virology (Medical University of Vienna)
2006 – 2015	Training as a Specialist in Virology at the Department of Virology (Medical University of Vienna)
2013 – 2014	Additional Training in „Hygiene, Microbiology and Preventive Medicine“ at the Institute of Environmental Health (Medical University of Vienna, Prof. Dr. Michael Kundi)
2014 – 2015	Additional Training in „Internal Medicine“ at the First Medical Department of the Hanusch Hospital, Vienna (Prof. Dr. Klaus Klaushofer)
since 2015	Medical consultant in Virology
2015	Venia docendi for Virology, Title of the habilitation thesis „T-cell response and T-cell associated chemokines in the clinical-virological diagnosis of Hepatitis C virus and Human Cytomegalovirus infections.“
2015 - 2018	Completion of a qualification agreement to become an Assoc.Prof.
since 2024	Medical consultant in Clinical Microbiology and Virology

ADDITIONAL TRAINING, PERIODS ABROADS, GRANTS, AWARDS, MEMBERSHIP OF ORGANIZATIONS

since 2024	Country Ambassador for Austria of the American Society for Microbiology (ASM)
2024	President-Elect of the Austrian Society for Hygiene, Microbiology and Preventive Medicine
since 2023	Member of the Austrian National Polio-Eradication Committee of the Federal Ministry of Health
since 2023	Member of the Austrian Society for Vaccinology
since 2021	Board Member of the Austrian Society for Hygiene, Microbiology and Preventive Medicine
since 2021	Member of the Austrian National Measles-Rubella Committee of the Federal Ministry of Health
since 2021	Head of the National Reference Laboratory for Measles, Mumps, Rubella and Hepatitis Viruses in Austria
since 2021	Member of the American Society for Microbiology
since 2020	Member of the Austrian Association for Quality Assurance and Standardization of Medical and Diagnostic Tests (ÖQUASTA)
2020	Grant Acquisition for the project "Diagnosis of SARS-CoV-2 infections and assessment of seroprevalence using antibody assays with the highest performance", Medical Scientific Fund of the Mayor of the City of Vienna
2016 – 2017	Research stay at the University of Helsinki, Finland, Department for Virology (duration: 10 months, host: Prof. Dr. Klaus Hedman)
2016	Acquisition of an Erwin-Schrödinger Grant of the Austrian Science Fund
2016	Scientific Award „Clinical Virology“ of the German Association for the Control of Viral Diseases e.V. (DVV) and the German Society for Virology (GfV)
since 2016	Member of the Joint Diagnostic Commission of the German Association for the Control of Viral Diseases e.V. (DVV) and the German Society for Virology (GfV)
2013	Completion of the Certificate Programme „Medical Education Vienna“
2011	Research stay at the University of Helsinki, Finland, Department for Virology (host: Prof. Dr. Klaus Hedman)
2011	Research stay at the Department of Pathology at the University of Cologne, Germany (Prof. Dr. Margarete Odenthal)
2009	Austrian „Hygiene-Award“ of the Austrian Association for Hygiene, Microbiology and Preventive Medicine
since 2009	Member of the European Society for Clinical Virology (ESCV)
2006	Advanced Training in the analysis of virus-specific immune responses, Monothematic Conference and Training of EASL, London, UK

ACTIVITIES AND RESPONSIBILITIES AT THE CENTER FOR VIROLOGY

1. RESEARCH

MAIN RESEARCH INTERESTS

Serology in Clinical Virology: Development, Establishment, and Evaluation of Antibody Assays (e.g., avidity assays, surrogate-neutralization tests, epitope-type specificity tests, immunoblots, microarrays); Assays for Biomarkers for the clinical severity of virus infections (e.g., T-cell associated chemokines)

LIST OF PUBLICATIONS (see below)

INTEGRATION INTO THE INTERNATIONAL RESEARCH COMMUNITY

Ongoing participation in international conferences and symposia with own scientific contribution

ONGOING ACTIVITY AS REVIEWER OF SCIENTIFIC JOURNALS

e.g., Journal of Clinical Virology, Journal of Medical Virology, American Journal of Transplantation, Clinical Microbiology and Infection, Microbiology Spectrum, Journal of Infectious Diseases and others

INTERNATIONAL AND NATIONAL COOPERATIONS

- University of Helsinki, Department for Virology, Prof. Dr. K. Hedman
- Medical University of Vienna, Department of Internal Medicine III, Nephrology and Haemodialysis, Prof. Dr. G. Bond, Prof. Dr. R. Reindl-Schwaighofer, Dr. Michael Eder
- Medical University of Vienna, Department of Internal Medicine III, Gastroenterology and Hepatology, Prof. T. Reiberger, Dr. Georg Semmler
- Medical University of Vienna, Department of Cardiothoracic Surgery, Prof. Dr. W. Klepetko. Prof. P. Jaksch
- Clinic Favoriten, 4th Medical Department, Department of Infectious Diseases and Tropical Medicine, PD Dr. A. Zoufaly, Dr. Marianna Traugott
- Clinic Penzing, Department of Respiratory and Critical Care Medicine, PD Dr. Marie Breyer

2. TEACHING

ONGOING TEACHING OF VIROLOGY AT THE MEDICAL UNIVERSITY OF VIENNA (MEDICAL STUDIES, N202)

- Ongoing organization and autonomous holding of lectures and seminars
- Creation of questions for summative integrated examinations
- Definition and elaboration of teaching contents
- Design of textbook content and learning materials
- Supervision and mentoring of dissertations and diploma theses
- Training of tutors for the seminar "Clinical Virology"
- Completion of the Certificate Programme „Medical Education Vienna“

3. CLINICAL ACTIVITY, NATIONAL REFERENCE LABORATORIES

since 2021 **Head of the National Reference Laboratory for Measles, Mumps and Rubella**

since 2021 **Head of the National Reference Laboratory for Hepatitis Viruses**

since 2017 **Head of the laboratory for serological diagnostics at the Center for Virology**

since 2015 **Medical Consultant for Virology**

since 2024 **Medical Consultant for Clinical Microbiology and Virology**

- Establishment, establishment, and evaluation of serological assays for the virological diagnostics
- Coordination of laboratory work in routine diagnostics
- Examination and treatment of patients in the outpatient clinic at the Center for Virology
- Quality Management

4. SCIENTIFIC DIRECTOR OF NATIONAL EXTERNAL QUALITY ASSESSMENT (EQA) ROUNDS OF THE AUSTRIAN ASSOCIATION FOR QUALITY ASSURANCE AND STANDARDIZATION OF MEDICAL AND DIAGNOSTIC TESTS (ÖQUASTA)

- since 2021: Scientific Director for the National EQAs for Hepatitis A, Hepatitis B, Hepatitis C antibodies, Hepatitis C PCR, Rubella, Herpes, and Rash-like Virus infections
- since 2020: Scientific Director of the National EQA for SARS-CoV-2 Antibodies

5. PUBLIC RELATIONS AND SCIENTIFIC COMMUNICATION

- continuous contributions to the Austrian Medical Newspaper
- ongoing interviews for newspaper articles (e.g., on the topics of measles)
- ongoing radio and television interviews

5. ORGANISATIONAL AND ADMINISTRATIVE TASKS

- Head of the Incoming Sample Department
- Deputy Data Protection Coordinator

LANGUAGES

- German (native language)
- English (perfect command written and spoken)

LIST OF PUBLICATIONS

* publications contributing to viral diagnosis

A. as FIRST, LAST, and/or CORRESPONDING AUTHOR

- * Springer DN, Borsodi C, Camp JV, Redlberger-Fritz M, Holzmann H, Kundi M, Aberle JH, Stiasny K, **Weseslindtner L**. *Seroprevalence against measles, Austria, stratified by birth years 1922 to 2024*. Euro Surveill. 2025; 30(16):2400684. doi: 10.2807/1560-7917.ES.2025.30.16.2400684.
- * Springer DN, Daller S, Knappik M, Prüger K, Hartl S, Breyer-Kohansal R, Puchhammer-Stöckl E, Aberle JH, **Weseslindtner L**, Breyer MK. *A Multivariant Surrogate Virus Neutralization Test Demonstrates Distinct SARS-CoV-2-Specific Antibody Responses in People Living with HIV after a Fourth Monovalent mRNA Vaccination or an Omicron Breakthrough Infection*. Diagnostics. 2024; 14(8):822. doi: 10.3390/diagnostics14080822.
- * Springer DN, Hörtl E, Prüger K, Puchhammer-Stöckl E, Aberle JH, Stiasny K, **Weseslindtner L**. *Measuring Variant-Specific Neutralizing Antibody Profiles after Bivalent SARS-CoV-2 Vaccinations Using a Multivariant Surrogate Virus Neutralization Microarray*. Vaccines. 2024; 12:94. doi: 10.3390/vaccines12010094.
- * Springer DN, Reuberger E, Borsodi C, Puchhammer-Stöckl E, **Weseslindtner L**. *Comparison of anti-nucleocapsid antibody assays for the detection of SARS-CoV-2 Omicron vaccine breakthroughs after various intervals since the infection*. J Med Virol. 2023; 95:e29229. doi: 10.1002/jmv.29229.
- * Aschauer C, Heinzl A, Stiasny K, Borsodi C, Hu K, Koholka J, Winnicki W, Kainz A, Haslacher H, Oberbauer R, Reindl-Schwaighofer R, **Weseslindtner L**. *Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines*. Viruses 2023; 15:1624. doi: 10.3390/v15081624.
- * Springer DN, Traugott M, Reuberger E, Kothbauer KB, Borsodi C, Nägeli M, Oelschlägel T, Kelani H, Lammel O, Deutsch J, Puchhammer-Stöckl E, Hörtl E, Aberle JH, Stiasny K, **Weseslindtner L**. *A Multivariant Surrogate Neutralization Assay Identifies Variant-Specific Neutralizing Antibody Profiles in Primary SARS-CoV-2 Omicron Infection*. Diagnostics 2023; 13:2278. doi: 10.3390/diagnostics13132278.
- * Buchta C, Springer D, Jovanovic J, Borsodi C, Weidner L, Sareban N, Radler U, Müller MM, Griesmacher A, Puchhammer-Stöckl E, Wagner T, Jungbauer C, Stiasny K, **Weseslindtner L**. *Three rounds of a national external quality assessment reveal a link between disharmonic anti-SARS-CoV-2 antibody quantifications and the infection stage*. Clin Chem Lab Med. 2023 the 10th of February. doi: 10.1515/cclm-2022-1161.
- * Graninger M, Jani CM, Reuberger E, Prüger K, Gaspar P, Springer DN, Borsodi C, Weidner L, Rabady S, Puchhammer-Stöckl E, Jungbauer C, Hörtl E, Aberle JH, Stiasny K, **Weseslindtner L**. *Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference*. Microbiol Spectr. 2023;11(1):e0231422. doi: 10.1128/spectrum.02314-22.
- * Springer DN, Perkmann T, Jani CM, Mucher P, Prüger K, Marculescu R, Reuberger E, Camp JV, Graninger M, Borsodi C, Deutsch J, Lammel O, Aberle SW, Puchhammer-Stöckl E, Haslacher H, Hörtl E, Aberle JH, Stiasny K, **Weseslindtner L**. *Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant*. Microbiol Spectr. 2022; e0212922. doi: 10.1128/spectrum.02129-22.
- * Hoepler WP, Weidner L, Traugott MT, Neuhold S, Meyer EL, Zoufaly A, Seitz T, Kitzberger R, Baumgartner S, Pawelka E, Karolyi M, Grieb A, Hind J, Laferl H, Friese E, Wenisch C, Aberle SW, Aberle JH, **Weseslindtner L**, Jungbauer C. *Adjunctive treatment with high-titre convalescent plasma in severely and critically ill COVID-19 patients - a safe but futile intervention*.

- A comparative cohort study.* Infect Dis. 2021; 53: 820-829. doi: 10.1080/23744235.2021.1940271.
- * Semmler G, Aberle SW, Griebler H, Richter L, Schmid D, Stiasny K, Holzmann H, **Weseslindtner L.** *Performance of Four IgM Antibody Assays in the Diagnosis of Measles Virus Primary Infection and Cases with a Serological Profile Indicating Reinfection.* J Clin Microbiol. 2021; 59:e02047-20. doi: 10.1128/JCM.02047-20.
 - * Semmler G, Traugott MT, Graninger M, Hoepler W, Seitz T, Kelani H, Karolyi M, Pawelka E, Aragón de La Cruz S, Puchhammer-Stöckl E, Aberle SW, Stiasny K, Zoufaly A, Aberle JH, **Weseslindtner L.** *Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.* J Clin Microbiol. 2021; 59:e02890-20. doi: 10.1128/JCM.02890-20.
 - * Jungbauer C, **Weseslindtner L,** Weidner L, Gänsdorfer S, Farcet MR, Gschaider-Reichhart E, Kreil TR. *Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations.* Transfusion. 2021 Jan;61(1):12-16. doi: 10.1111/trf.16119.
 - * Orth-Höller D, Eigentler A, Stiasny K, **Weseslindtner L,** Möst J. *Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection.* J Infect. 2020 doi: 10.1016/j.jinf.2020.09.015.
 - * Traugott MT, Hoepler W, Seitz T, Baumgartner S, Karolyi M, Pawelka E, Friese E, Neuhold S, Kelani H, Thalhammer F, Zoufaly A, Laferl H, Aberle JH, Wenisch C, Puchhammer-Stöckl E, Stiasny K, Aberle SW, **Weseslindtner L.** *Diagnosis of COVID-19 using multiple antibody assays in two cases with negative PCR results from nasopharyngeal swabs.* Infection. 2020 doi: 10.1007/s15010-020-01497-2.
 - * Orth-Höller D, Eigentler A, **Weseslindtner L (shared last-authorship),** Möst J. *Antibody kinetics in primary- and secondary-care physicians with mild to moderate SARS-CoV-2 infection.* Emerg Microbes Infection. 2020, 9:1692-1694. doi: 10.1080/22221751.2020.1793690.
 - * Semmler G, Griebler H, Aberle SW, Stiasny K, Richter L, Holzmann H, **Weseslindtner L.** *Elevated CXCL10 serum levels in Measles virus primary infection and reinfection correlate with the serological stage and hospitalization status.* J Infect Dis. 2020, 222: 2030-2034. doi: 10.1093/infdis/jiaa326.
 - * Traugott M, Aberle SW, Aberle JH, Griebler H, Karolyi M, Pawelka E, Puchhammer-Stöckl E, Zoufaly A, **Weseslindtner L.** *Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests.* J Infect Dis. 2020, 222:362-366. doi: 10.1093/infdis/jiaa305.
 - * **Weseslindtner L,** Hedman L, Wang Y, Strassl R, Helanterä I, Aberle SW, Bond G, Hedman K. *Longitudinal assessment of the CXCL10 blood and urine concentration in kidney transplant recipients with BK polyomavirus replication-a retrospective study.* Transpl Int. 2020, 33: 555-566. doi: 10.1111/tri.13584.
 - * Wang Y, Strassl R, Helanterä I, Aberle SW, Bond G, Hedman K, **Weseslindtner L.** *Multiplex analysis of Human Polyomavirus diversity in kidney transplant recipients with BK virus replication.* J Clin Virol. 2019; 120:6-11.
 - * **Weseslindtner L,** Aberle JH, Hedman L, Hedman K. *The chemokine CXCL-10 is a marker for the infection stage in individuals with Parvovirus B19 DNAemia.* J Infect Dis 2017; 215:214-220.
 - * **Weseslindtner L,** Görzer I, Roedl K, Küng E, Jaksch P, Klepetko W, Puchhammer-Stöckl E. *Intrapulmonary Human Cytomegalovirus replication in lung transplant recipients is associated with a rise of CCL-18 and CCL-20 chemokine levels.* Transplantation 2017; 101:197-203
 - * **Weseslindtner L,** Macheleidt I, Eiseheid H, Strassl R, Hofer H, Popow-Kraupp T, Dienes HP, Holzmann H, Odenthal M. *Micro RNAs mir-106a, mir-122 and mir-197 are increased in severe acute viral hepatitis with coagulopathy.* Liver Int 2016; 36: 353-360.

- * **Weseslindtner L**, Görzer I, Küng E, Roedl K, Jaksch P, Klepetko W, Puchhammer-Stöckl E. *High CXCL-16 Levels Correlate with Symptomatic Disease in Lung Transplant Recipients with Human Cytomegalovirus Replication in the Allograft*. Am J Transplant 2014; 14: 2406-1411.
- * **Weseslindtner L**, Kerschner H, Kundi M, Steinacher D, Simon B, Jaksch P, Hatos-Agyi L, Scheed A, Klepetko W, Puchhammer-Stöckl E. *Association of human cytomegalovirus DNAemia and specific granzyme B responses in lung transplant recipients*. Clin Exp Immunol. 2013; 173:438-443.
- * **Weseslindtner L**, Kerschner H, Steinacher D, Nachbagauer R, Kundi M, Jaksch P, Simon B, Hatos-Agyi L, Scheed A, Klepetko W, Puchhammer-Stöckl E. *Prospective Analysis of Human Cytomegalovirus DNAemia and Specific CD8+ T-Cell Responses in Lung Transplant Recipients*. Am J Transplant. 2012; 12:2172-80.
- * **Weseslindtner L**, Nachbagauer R, Kundi M, Jaksch P, Kerschner H, Simon B, Hatos-Agyi L, Scheed A, Aberle JH, Klepetko W, Puchhammer-Stöckl E. *Human cytomegalovirus infection in lung transplant recipients triggers a CXCL-10 response*. Am J Transplant. 2011; 11:542-52.
- * **Weseslindtner L**, Neumann-Haefelin C, Viazov S, Haberstroh A, Kletzmayer J, Aberle JH, Timm J, Ross SR, Klauser-Braun R, Baumert TF, Roggendorf M, Thimme R, Holzmann H. *Acute infection with a single hepatitis C virus strain in dialysis patients: Analysis of adaptive immune response and viral variability*. J Hepatol. 2009; 50:693-704.

B. CO-AUTHOR:

- * Florian DM, Bauer M, Popovitsch A, Fae I, Springer DN, Graninger M, Traugott M, **Weseslindtner L**, Aberle SW, Fischer G, Kundi M, Stiasny K, Zoufaly A, Landry SJ, Aberle JH. *Enhanced and long-lasting SARS-CoV-2 immune memory in individuals with common cold coronavirus cross-reactive T cell immunity*. Front Immunol. 2025;16:1501704. doi: 10.3389/fimmu.2025.1501704. eCollection 2025.
- * Jorda A, Prager M, Pracher L, Haselwanter P, Jackwerth M, Al Jalali V, Yildiz E, Leutzendorff A, Weber M, Yourieva S, Kammerer P, Pecho T, Decaminada A, Ederer L, Wiedermann U, **Weseslindtner L**, Redlberger-Fritz M, Bergmann F, Zeitlinger M. *Immunogenicity, safety, and reactogenicity of concomitant administration of the novavax vaccine against Omicron XBB.1.5 (NVX-CoV2601) and a 20-valent pneumococcal conjugate vaccine in adults aged ≥60 years: A randomised, double-blind, placebo-controlled, non-inferiority trial*. J Infect. 2025; 90(2):106405. doi: 10.1016/j.jinf.2024.106405.
- * Reindl-Schwaighofer R, Heinzel A, Raab L, Strassl R, Herz CT, Regele F, Doberer K, Helk O, Specht P, Aschauer C, Hu K, Jagoditsch R, Reiskopf B, Böhmig GA, Benka B, Mahr B, Stiasny K, **Weseslindtner L**, Kammer M, Wekerle T, Oberbauer R. *Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4/5 variants-a prospective cohort study (RESCUE-TX)*. EBioMedicine. 2024; 109:105417. doi: 10.1016/j.ebiom.2024.105417.
- * Balcar L, Schwarz M, Dorn L, Jachs M, Hartl L, **Weseslindtner L**, Pfisterer N, Hennlich B, Stückler A, Strassl R, Voill-Glaninger A, Hübl W, Willheim M, Köhrer K, Jansen-Skoupy S, Tomez S, Krugluger W, Madl C, Burghart L, Antonitsch L, Weidinger G, Riedl F, Laferl H, Hind J, Wenisch C, Sebesta C, Wachter-Welzl J, Watzl P, Neuhauser M, Chromy D, Mandorfer M, Schmid D, Gschwantler M, Reiberger T, Maieron A, Bauer DJM, Schwarz C. *A systematic PCR record-based re-call of HCV-RNA-positive people enables re-linkage to care and HCV elimination in Austria - The ELIMINATE project*. Liver Int. 2024; 44(12):3151-3163. doi: 10.1111/liv.16076.
- * Springer DN, Camp JV, Aberle SW, Deutsch J, Lammel O, **Weseslindtner L**, Stiasny K, Aberle JH. *Neutralization of SARS-CoV-2 Omicron XBB.1.5 and JN.1 variants after COVID-19 booster-vaccination and infection*. J Med Virol. 2024; 96(7):e29801. doi: 10.1002/jmv.29801.

- * Eder M, Schrag TA, Havel EF, Kainz A, Omic H, Doberer K, Kozakowski N, Körmöczy GF, Schönbacher M, Fischer G, Strassl R, Breuer M, **Weseslindtner L**, Hauptenthal F, Böhmig GA, Puchhammer-Stöckl E, Bond G, Görzer I, Eskandary F. *Polyomavirus Nephropathy in ABO Blood Group-Incompatible Kidney Transplantation: Torque Teno Virus and Immunosuppressive Burden as an Approximation to the Problem*. *Kidney Int Rep*. 2024; 9(6):1730-1741. doi: 10.1016/j.ekir.2024.04.003.
- * Buchta C, Aberle SW, Görzer I, Griesmacher A, Müller MM, Neuwirth E, Puchhammer-Stöckl E, Weseslindtner L, Camp JV. *External quality assessments for SARS-CoV-2 genome detection in Austria: A comparison of the first postpandemic round with results from the pandemic era*. *Wien Klin Wochenschr*. 2024; 136(15-16):429-438. doi: 10.1007/s00508-024-02353-1.
- * Buchta C, Aberle SW, Allerberger F, Benka B, Görzer I, Griesmacher A, Hübl W, Huf W, Kapiotis S, Müller MM, Neuwirth E, Puchhammer-Stöckl E, **Weseslindtner L**, Camp JV. *Performance of SARS-CoV-2 nucleic acid amplification testing in Austria as measured by external quality assessment schemes during 3 years of the COVID-19 pandemic: an observational retrospective study*. *Lancet Microbe* 2024; 4:e1015-e1023. doi: 10.1016/S2666-5247(23)00286-0.
- * Springer DN, Medits I, **Weseslindtner L**, Stiasny K, Aberle JH. SARS-CoV-2 neutralising antibody response to bivalent booster after omicron infection. *Lancet Microbe* 2024; 5:e8. doi: 10.1016/S2666-5247(23)00293-8.
- * Schwarz C, Bauer D, Dorn L, Jachs M, Hartl L, Chromy D, **Weseslindtner L**, Pfisterer N, Hennlich B, Stückler A, Strassl R, Voill-Glaninger A, Hübl W, Willheim M, Köhrer K, Jansen-Skoupý S, Tomez S, Krugluger W, Madl C, Schwarz M, Balcar L, Semmler G, Brinkmann L, Burghart L, Antonitsch L, Weidinger G, Riedl F, Laferl H, Kurteva V, Traugott M, Hind J, Wenisch C, Aburaia A, Sebesta C, Schmid D, Rothweiler S, Remetic J, Gschwantler M, Maieron A, Reiberger T. *ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria*. *Wien Klin Wochenschr* 2023; doi: 10.1007/s00508-023-02275-4.
- * Springer DN, Bauer M, Medits I, Camp JV, Aberle SW, Burtscher C, Höltl E, **Weseslindtner L**, Stiasny K, Aberle JH. *Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants*. *NPJ Vaccines* 2023; 8:110. doi: 10.1038/s41541-023-00708-9.
- * Perkmann T, Springer DN, Mucher P, Wolzt M, **Weseslindtner L**, Haslacher H. *Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations*. *J Clin Virol Plus*. 2023 Aug;3(3):100157.
- * Buchta C, Zeichhardt H, Aberle SW, Camp JV, Görzer I, **Weseslindtner L**, Puchhammer-Stöckl E, Huf W, Benka B, Allerberger F, Mielke M, Griesmacher A, Müller MM, Schellenberg I, Kammel M. *Design of external quality assessment schemes and definition of the roles of their providers in future epidemics*. *Lancet Microbe* 2023;S2666-5247(23)00072-1.
- * Sieber J, Schmidthaler K, Kopanja S, **Weseslindtner L**, Stiasny K, Götzinger F, Graf A, Krotka P, Hoz J, Schoof A, Dwivedi V, Frischer T, Szépfalusi Z. *Limited role of children in transmission of SARS-CoV-2 virus in households-Immunological analysis of 26 familial clusters*. *Pediatr Allergy Immunol*. 2023 Jan;34(1):e13913. doi: 10.1111/pai.13913.
- * Stiasny K, **Weseslindtner L**, Heinzl A, Camp JV, Oberbauer R, Reindl-Schwaighofer R. *SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab*. *Transpl Int* 2022; 35:10906. doi: 10.3389/ti.2022.10906.
- * Laner-Plamberger S, Lindlbauer N, Weidner L, Gänsdorfer S, **Weseslindtner L**, Held N, Lauth W, Zimmermann G, Kern JM, Föttinger F, Ombres L, Jungbauer C, Rohde E, Grabner C. *SARS-CoV-2 IgG Levels Allow Predicting the Optimal Time Span of Convalescent Plasma Donor Suitability*. *Diagnostics (Basel)*. 2022; 12:2567. doi: 10.3390/diagnostics12112567.

- * Mayr L, Steinmaurer T, **Weseslindtner L**, Madlener S, Strassl R, Gojo J, Azizi AA, Slavic I, Peyrl A. *Viral infections in pediatric brain tumor patients treated with targeted therapies*. *Pediatr Blood Cancer*. 2023 Jan;70(1):e30065. doi: 10.1002/pbc.30065.
- * Medits I, Springer DN, Graninger M, Camp JV, Höltl E, Aberle SW, Traugott MT, Hoepler W, Deutsch J, Lammel O, Borsodi C, Puchhammer-Stöckl E, Zoufaly A, **Weseslindtner L**, Aberle JH, Stiasny K. *Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections*. *Front Immunol* 2022; 13:946318. doi: 10.3389/fimmu.2022.946318.
- * Mayer KA, Omic H, **Weseslindtner L**, Doberer K, Reindl-Schwaighofer R, Viard T, Tillgren A, Haindl S, Casas S, Eskandary F, Heinzl A, Kozakowski N, Kikić Ž, Böhmig GA, Eder M. *Levels of donor-derived cell-free DNA and chemokines in BK polyomavirus-associated nephropathy*. *Clin Transplant*. 2022:e14785. doi: 10.1111/ctr.14785.
- * Graninger M, Camp JV, Aberle SW, Traugott MT, Hoepler W, Puchhammer-Stöckl E, **Weseslindtner L**, Zoufaly A, Aberle JH, Stiasny K. *Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination*. *Front Immunol*. 2022; 13:888794. doi: 10.3389/fimmu.2022.888794.
- * Sieber J, Mayer M, Schmidthaler K, Kopanja S, Camp JV, Popovitsch A, Dwivedi V, Hoz J, Schoof A, **Weseslindtner L**, Szépfalusi Z, Stiasny K, Aberle JH. *Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron*. *Front Immunol*. 2022; 13:882456. doi: 10.3389/fimmu.2022.882456.
- * Wagner A, Garner-Spitzer E, Schötta AM, Orola M, Wessely A, Zwazl I, Ohradanova-Repic A, **Weseslindtner L**, Tajti G, Gebetsberger L, Kratzer B, Tomosel E, Kutschera M, Tobudic S, Pickl WF, Kundi M, Stockinger H, Novacek G, Reinisch W, Zielinski C, Wiedermann U. *SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients - A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease*. *Front Immunol*. 2022;13:889138. doi: 10.3389/fimmu.2022.889138.
- * Kopanja S, Gattlinger P, Schmidthaler K, Sieber J, Niepodziana K, Schleder T, **Weseslindtner L**, Stiasny K, Götzinger F, Pickl WF, Frischer T, Valenta R, Szépfalusi Z. *Characterization of the antibody response to SARS-CoV-2 in a mildly affected pediatric population*. *Pediatr Allergy Immunol*. 2022; 33:e13737. doi: 10.1111/pai.13737.
- * Rabady S, Hoffmann K, Brose M, Lammel O, Poggenburg S, Redlberger-Fritz M, Stiasny K, Wendler M, **Weseslindtner L**, Zehetmayer S, Kamenski G. *Symptoms and risk factors for hospitalization of COVID-19 presented in primary care : An exploratory retrospective study*. *Wien Klin Wochenschr*. 2022. 11:1-9. doi: 10.1007/s00508-021-01992-y.
- * Omić H, Kläger JP, Herkner H, Aberle SW, Regele H, **Weseslindtner L**, Schrag TA, Bond G, Hohenstein K, Watschinger B, Werzowa J, Strassl R, Eder M, Kikić Ž. *Clinical Relevance of Absolute BK Polyoma Viral Load Kinetics in Patients With Biopsy Proven BK Polyomavirus Associated Nephropathy*. *Front Med*. 2022. 8: 791087. doi: 10.3389/fmed.2021.791087. eCollection 2021.
- * Reindl-Schwaighofer R, Heinzl A, Mayrdorfer M, Jabbour R, Hofbauer TM, Merrelaar A, Eder M, Regele F, Doberer K, Spechtl P, Aschauer C, Koblishke M, Paschen C, Eskandary F, Hu K, Öhler B, Bhandal A, Kleibenböck S, Jagoditsch RI, Reiskopf B, Heger F, Bond G, Böhmig GA, Strassl R, **Weseslindtner L**, Indra A, Aberle JH, Binder M, Oberbauer R. *Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial*. *JAMA Intern Med*. 2022. 82:165-171. doi: 10.1001/jamainternmed.2021.7372.
- * Nurmi V, Hedman L, Perdomo MF, **Weseslindtner L**, Hedman K. *Comparison of approaches for IgG avidity calculation and a new highly sensitive and specific method with broad dynamic range*. *Int J Infect Dis*. 2021 Sep;110:479-487. doi: 10.1016/j.ijid.2021.05.047.
- * Breyer MK, Breyer-Kohansal R, Hartl S, Kundi M, **Weseslindtner L**, Stiasny K, Puchhammer-Stöckl E, Schrott A, Födinger M, Binder M, Fiedler M, Wouters EFM, Burghuber OC. *Low SARS-*

CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown. Sci Rep. 2021. 11:10158. doi: 10.1038/s41598-021-89711-5.

- * Bartko J, Zehetmayer S, **Weseslindtner L**, Stiasny K, Schloegl A, Forjan E, Zwettler E, Krauter A, Keil F, Sédille-Mostafaie N. *Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe.* J Clin Med. 2021; 10:1909. doi: 10.3390/jcm10091909.
- * Schubert L, Strassl R, Burgmann H, Dvorak G, Karer M, Kundi M, Kussmann M, Lagler H, Lötsch F, Milacek C, Obermueller M, Oesterreicher Z, Steininger C, Stiasny K, Thalhammer F, Traby L, Vass Z, Vossen MG, **Weseslindtner L**, Winkler S, Tobudic S. *A Longitudinal Seroprevalence Study Evaluating Infection Control and Prevention Strategies at a Large Tertiary Care Center with Low COVID-19 Incidence.* Int J Environ Res Public Health. 2021; 18:4201. doi: 10.3390/ijerph18084201.
- * Scharrer S, Kutschera M, **Weseslindtner L**, Primas C, Vogelsang H. *Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.* Eur J Gastroenterol Hepatol. 2021; 33: 443-447. doi: 10.1097/MEG.0000000000002094.
- * Szépfalusi Z, Schmidthaler K, Sieber J, Kopanja S, Götzinger F, Schoof A, Hoz J, Willinger B, Makristathis A, **Weseslindtner L**, Stiasny K, Bohle B, Krotka P, Graf A, Frischer T. *Lessons from low seroprevalence of SARS-CoV-2 antibodies in schoolchildren: A cross-sectional study.* Pediatr Allergy Immunol. 2021; 32:762-770. doi: 10.1111/pai.13459.
- * Hoepler W, Traugott MT, Christ G, Kitzberger R, Pawelka E, Karolyi M, Seitz T, Baumgartner S, Kelani H, Wenisch C, Laferl H, Zoufaly A, **Weseslindtner L**, Neuhold S. *Clinical and Angiographic Features in Three COVID-19 Patients with Takotsubo Cardiomyopathy.* Case Report. SN Compr Clin Med. 2021; 3:263-268. doi: 10.1007/s42399-020-00683-5.
- * Stepien N, **Weseslindtner L**, Seidl R, Geldner J, Golej J, Schmook MT, Peyrl A. *An adolescent with herpes simplex encephalitis, presenting with mild symptoms and rapid deterioration: A case report.* SAGE Open Med Case Rep. 2020 the 6th of December;8:2050313X20977142. doi: 10.1177/2050313X20977142. eCollection 2020.
- * Koblichke M, Traugott MT, Medits I, Spitzer FS, Zoufaly A, **Weseslindtner L**, Simonitsch C, Seitz T, Hoepler W, Puchhammer-Stöckl E, Aberle SW, Födinger M, Bergthaler A, Kundi M, Heinz FX, Stiasny K, Aberle JH. *Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity.* Front Med. 2020. 7: 592629. doi: 10.3389/fmed.2020.592629.
- * Weidner L, Gänsdorfer S, Unterweger S, **Weseslindtner L**, Drexler C, Farcet M, Witt V, Schistal E, Schlenke P, Kreil TR, Jungbauer C. *A Quantification of SARS-CoV-2 antibodies with eight commercially available immunoassays.* J Clin Virol. 2020. doi: 10.1016/j.jcv.2020.104540.
- * Seitz T, Hoepler W, **Weseslindtner L**, Aberle JH, Aberle SW, Puchhammer-Stoeckl E, Baumgartner S, Traugott M, Karolyi M, Pawelka E, Niculescu I, Friesse E, Neuhold S, Stahl D, Madl C, Zoufaly A, Wenisch C, Laferl H. *Successful management of the first reported case in Austria of COVID-19 with ARDS.* Infection. 2020 48:647-651. doi: 10.1007/s15010-020-01458-9.
- * Liimatainen H, **Weseslindtner L**, Strassl R, Aberle SW, Bond G, Auvinen E. *Next-generation sequencing shows marked rearrangements of BK polyomavirus that favor but are not required for polyomavirus-associated nephropathy.* J Clin Virol. 2020; 122:104215. doi: 10.1016/j.jcv.2019.104215.
- * Simon B, **Weseslindtner L**, Görzer I, Pollak K, Jaksch P, Klepetko W, Puchhammer-Stöckl E. *Subclass-specific antibody responses to human cytomegalovirus in lung transplant recipients and their association with constant heavy immunoglobulin G chain polymorphism and virus replication.* J Heart Lung Transplant. 2016; 35:370-377.
- * Aichelburg MC, **Weseslindtner L**, Mandorfer M, Strassl R, Rieger A, Reiberger T, Puchhammer-Stöckl E, Grabmeier-Pfistershammer K. *Association of CMV-Specific T Cell-Mediated Immunity*

with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals. PLoS One. 2015; 31, 10(8):e0137096.

- * Haloschan M, Bettesch R, Görzer I, **Weseslindtner L**, Kundi M, Puchhammer-Stöckl E. *TTV DNA plasma load and its association with age, gender, and HCMV IgG serostatus in healthy adults.* Age. 2014; 36:9716. doi: 10.1007/s11357-014-9716-2.
- * Bejvl I, **Weseslindtner L**, Strassl R, Jaksch P, Kundi M, Klepetko W, Puchhammer-Stöckl E. *Analysis of plasma surfactant protein D levels in lung transplant recipients.* Transpl Infect Dis. 2013; 15 :645-51.
- * Aberle JH, Perstinger G, **Weseslindtner L**, Sinzinger U, Gurguta C, Steindl-Munda P, Kundi M, Popow-Kraupp T, Ferenci P, Holzmann H. *CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance.* J Infect Dis. 2007; 195:1315-9.
- * Aberle JH, Formann E, Steindl-Munda P, **Weseslindtner L**, Gurguta C, Perstinger G, Grilnberger E, Laferl H, Dienes HP, Popow-Kraupp T, Ferenci P, Holzmann H. *Prospective study of viral clearance and CD4(+) T-cell response in acute hepatitis C primary infection and reinfection.* J Clin Virol. 2006; 36:24-31.